Prior to NEA, he held positions at The Medicines Company, Morgan Stanley Venture Partners and Lehman Brothers. Dr. Torti has served as Vant Investment Chair of Roivant Pharma, a business unit of Roivant Sciences, since August 2018. New Enterprise Associates. Mr. Jackson holds a B.S. in Finance from Loyola University. Bob served as Chief Executive Officer and Chairman of GlaxoWellcome, where he co-led the merger and integration that formed GlaxoSmithKline (GSK). Member of the Nominating and Governance Committee. He currently serves on the Board of Directors of ImmunoGen, Inc., Blueprint Medicines, Idera Pharmaceuticals and Audentes Therapeutics. Dr. Makower has dedicated his life to the creation of medical technologies which improve the quality of life for patients. While at McKinsey, he co-led the biotechnology practice and focused on topics ranging from strategy to operations and led initiatives in areas such as personalized medicine and immunotherapy. Executive Chairman of the Board Carol Gallagher, PharmD. After the sale to Novartis, she was named CEO and ran the company as a wholly-owned subsidiary of Novartis. Desktop Metal, Burlington, Massachusetts, USA, has announced the appointment of Scott Dussault to its board of directors effective December 18, 2020. LYZZ Capital, Board Member. President, CEO, Board Member Terry Gould . . Previously he served as Executive Vice President for Medical and Regulatory strategy and as the Senior Vice President of Medical and Regulatory Affairs at Synageva BioPharma Corp. Dr. Goldberg also worked in a variety of senior management positions at Genzyme Corporation, including as Senior Vice President and Therapeutic Group Head for Oncology and Personalized Genetic Health Clinical Development. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical, and healthcare services sectors. Dr. Kapil Dhingra is an accomplished medical oncologist and pharmaceutical executive with a proven track record in academic research, patient care, and drug development. Corporate Headquarters New Enterprise Associates. from the Indian Institute of Technology. Under Mr. Jackson's leadership, Celator successfully developed Vyxeos® for treatment of newly diagnosed AML patients. His versatile career has included operational roles covering drug development, manufacturing, financing, licensing, and M&A. Cambridge, MA 02142, 180 Varick Street, 6th Floor RESTON, Va.—March 4, 2014—Appian, the market leader in modern business process managment (BPM) software, today announced that Harry Weller, General Partner at New Enterprise Associates (NEA), has joined Appian’s board of directors, in conjunction with the firm’s recent minority investment. Prior to TCR2, Garry served as Chief Financial Officer at DaVita Healthcare and Chief Operating Officer at Regulus Therapeutics. He is also an active member of the Big Brothers of Massachusetts Bay program. We are a global venture capital firm with a mission to make the world better by helping founders build great companies that improve the way we live, work and play. from Harvard College and an M.D. Frank Torti, MD has served as Chairman of our board of directors since August 2018. Company profile page for New Enterprise Associates Inc including stock price, company news, press releases, executives, board members, and contact information Dr. Magnani is the discoverer of Sialyl Lea and its functions. . He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. New Enterprise Associates, Board Member. Prior to that, she was Executive Vice President and Chief Commercial Officer at Incyte, leading commercial operations for that company’s launch of first-in-class, first-in-disease oncology product Jakafi®. Ali is a general partner at New Enterprise Associates (NEA). Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. From 1989 to 1996, Kapil was a faculty member at The University of Texas M.D. He received a B.Sc. He serves as co-chair of the Scientific Advisory Board of the Institute for Bioscience and Biotechnology Research (IBBR) at the University of Maryland. He has more than 25 years of experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems Inc., Centocor Inc., a division of Johnson & Johnson, Eximias Pharmaceutical and YM BioSciences. Under his leadership, Roche established alliances with more than 75 venture-backed biotech companies worldwide and transformed its R&D pipeline into an industry leader. Website Design & Development: Graphic Beans, Site Map | Terms of Use | Privacy | Contact Us, APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia, New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition, GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model, GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer (CBO), and then served as President and CBO before being named its CEO in 2017. Dr. Barrett joined venture capital firm New Enterprise Associates (NEA) in 2001 as a General Partner. "We are pleased to add Jake and Simos to the Regulus board. His teams have progressed multiple novel agents through development in oncology, cardiovascular disease, and retinal degeneration. Dr. Prior to that, Brad held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs and business development. in Business Administration from Eastern Illinois University. He has also led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc., President and CEO of Life Technologies and President and CEO of Bethesda Research Labs. Raj holds a B.A. Mr. Panero was the co-founder of XM Satellite Radio, Inc. and served as its Chief Executive Officer from 1998 to 2007. David Mott has served as our Chairman since January 2017 and as a Non-Executive Director since February 2015. M. James Barrett, Ph.D. — Chairman of the Board of Directors. Dr. Magnani is an expert in glycobiology, having discovered and characterized many carbohydrate tumor antigens, such as the FDA-approved cancer diagnostic, CA19-9. Board of Directors / Compensation Committee Informatica Mar 2014 - Aug ... Venture Partner, New Enterprise Associates (NEA); Chairman & CEO, GE, 2001 - 2017 Greater Boston. Present board memberships in addition to GlycoMimetics include Clovis Oncology, Proteostasis Therapeutics, and Senseonics. Board of Directors Ali Behbahani, M.D. Mr. Junius holds an undergraduate degree in Political Science from Boston College and a Master’s in Management from Northwestern University’s Kellogg School of Management. Scott Jackson served as Celator CEO and as a member of the Board of Directors from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc. from the University of Texas Health Science Center in Houston. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. Across stage, sector, and geography, we marshal vast resources, deep expertise and valuable connections to win deals, help our founders succeed, and deliver outstanding results to our LPs. He remained at the NIH for 10 years, finally serving as a tenured research chemist. Ms. Andrews received her M.B.A. from the University of Michigan and her B.A. Sam also serves as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR and Bayer. Mr. Pearson, a CPA, holds B.S. He also serves on the board of the Research Triangle Foundation of North Carolina, the Research Triangle Institute, and is Chairman of the GSK Foundation. from Brown University. degrees in Business Administration from the University of Delaware and in Accounting from the University of Maryland University College, as well as an M.S. He was the first to identify the binding domain to the selectins common to both Sialyl Lea and Sialyl Lex and used this information to develop potent selectin antagonists as drug candidates now in clinical trials. He is currently a member of the Boards of Directors of Replimune, Inc., Five Prime Therapeutics, Inc., Autolus Therapeutics plc, and Median Technologies, and has previously served on the boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, and Epitherapeutics, which were all acquired by major pharmaceutical companies. Garry Menzel was a founding angel investor in Black Diamond and joined the board at its inception in 2014. Robert (Bob) A. Ingram serves as Chairman of the Board of Black Diamond Therapeutics. He is also a member of the National Cancer Institute Experimental Therapeutics panel and a member of the New Drug Advisory Committee of the European Organisation for Research and Treatment of Cancer. degree from the All India Institute of Medical Sciences in New Delhi, India. Rajeev (Raj) Shah is Managing Partner at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life sciences, including companies developing novel drugs, medical devices, and diagnostics. He formerly served as a Non-Executive Director of Adaptimmune Limited since September 2014, initially in a capacity as a nominee of New Enterprise Associates 14 LP (NEA), one of our shareholders. Carol Gallagher, PharmD. He also developed fundamental technology for the identification of functional carbohydrate epitopes. from Cornell University, where he majored in Chemistry. Toronto, ON M5G 0B7 Canada. Previously, he helped co-found the U.S. subsidiary of BioCarb and became its international Vice President of Research. Paul Walker of New Enterprise Associates is appointed to the Board of Directors. He holds an A.B. Dr. Torti joined Roivant from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. Dr. Magnani received his Ph.D. from Princeton University and then joined the Laboratory of Biological Pharmacology of the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases (NIADDK) of the National Institutes of Health (NIH). Before his appointment as Black Diamond’s President and CEO, David was Vice Dean, Innovation & Entrepreneurship, and Associate Professor in Cancer & Stem Cell Biology, at Duke-NUS Medical School, Singapore, where he founded and built Duke-NUS’s Centre for Technology & Development, which  has developed a pipeline of innovation projects. We believe we’re better together, working as a team. She also served as Chair of the Maryland Life Sciences Advisory Board under former Governor Martin O’Malley. He also has an M.B.A. from the Stanford Graduate School of Business. from Harvard Medical School. Ali  received an M.D. His track record consists of successive outlier returns including Amira (sale), Okairos (sale), Speedel (sale), Quanticel (sale), Novira (sale), Flexion (2014 IPO), Crispr (2016 IPO), BioTie (sale), Jecure (sale), Inception (multiple sales), and Blue Rock (sale), and he continues to manage several other promising investments. Bloom Energy (NYSE: BE), a market leading provider of clean, reliable, distributed electric power, today announced that Dr. Michael J. Boskin, the Tully M. Friedman Professor of Economics and Wohlford Family Senior Fellow at Stanford University’s Hoover Institution, and Jeffrey Immelt, former Chairman and CEO of GE (NYSE: GE) and current Venture Partner of New Enterprise Associates, will join the … Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. CAMBRIDGE, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Paul Walker has been appointed to the Company’s Board of … Prior to co-founding GMI, Dr. Magnani founded and led a predecessor company, GlycoTech Corporation, as its President and CEO. document.write(new Date().getFullYear()); Mr. Junius has been a director of GlycoMimetics, Inc. since March 2016. Mrs. King also worked previously at ALZA Corporation in Palo Alto, CA and at Bain & Company in Boston. Both NEA and Sarissa Capital participated in … Mrs. King came to NEA after serving as a senior vice president of Novartis Corporation. Randy is a seasoned senior medical device executive and leader in the ophthalmic industry. He has authored several publications in leading scientific and business journals. Present board memberships in addition to … She received her B.A. Alex Mayweg, Ph.D., has served as a member of our board of directors since March 2017 and, from March 2017 to September 2019, served as our interim Chief Scientific Officer. Scott Gottlieb, M.D, is an American physician who worked as the 23rd Commissioner of the Food and Drug Administration (FDA).He served in the FDA from May 2017 until April 2019. He formerly served as a Non-Executive Director of Adaptimmune Limited since September 2014, initially in a capacity as a nominee of New Enterprise Associates 14 LP (NEA), one of our shareholders. Mr. Pearson led the company’s financial activities, including performance management, investor relations, SEC compliance, capital strategy and planning, until the company was acquired by SXC Health Solutions (now Catamaran Corporation) in 2012. She now serves on the board of the University of Maryland BioPark. Mr. Mathers is currently a partner at New Enterprise Associates, Inc., a global venture capital firm that invests in technology and healthcare companies, a position he has held since August 2008. Jeffrey Immelt currently serves as a Venture Partner on both the technology and healthcare investing teams at New Enterprise Associates (“NEA”). Dr. Nayeem joined NEA in January 2009 and focuses on investments in biopharmaceutical companies.She serves as a board observer for Epizyme, Omthera, Tesaro and Zyngenia and has also been involved in NEA’s investments in 3-V Biosciences and Prosensa. Brad combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Kapil founded KAPital Consulting, LLC, in 2008, a company dedicated to helping biotechnology, pharmaceutical, and diagnostic companies realize the clinical and commercial advances in oncology. Ms. Grayson is a Managing Partner of Construct Capital, a venture capital firm she co-founded in 2020. RESTON, Va.— March 4, 2014— Appian, the market leader in modern business process management (BPM) software, today announced that Harry Weller, General Partner at New Enterprise Associates (NEA), has joined Appian’s board of directors, in conjunction with the firm’s recent minority investment. Board of Directors. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania, where he graduated with Honors and was a Palmer Scholar, and a B.S. Prior to joining NEA, Ali worked as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. in Chemistry from Lewis & Clark College. David earned a Ph.D. in Biochemistry at Brandeis University and completed a joint post-doctoral fellowship, leading a collaboration in protein structure, function, and NMR dynamics between the labs of Steven Benkovic (Penn State) and Peter Wright at The Scripps Research Institute in La Jolla, California. In 2013, he received the NACD B. Kenneth West Lifetime Achievement Award from the National Association of Corporate Directors. Alex has served as a Managing Director at Versant Ventures, a healthcare investment firm, since March 2020, and previously served as a Partner from January 2018 to February 2020 and as a Venture Partner from January 2017 to December 2017 at Versant Ventures. Dr. Torti has served as Vant Investment Chair of Roivant Pharma, a business unit of Roivant Sciences, since August 2018. He earned an M.S. Ms. Grayson has served as a member of our Board of Directors since October 2015. UPDATE Dr. Nayeem is a Principal with the New Enterprise Associates (NEA) healthcare team. Dr. Magnani is co-founder and CSO of GlycoMimetics, Inc (GMI). Ms. Dr. Nayeem joined NEA in January 2009 and focuses on investments in biopharmaceutical companies.She serves as a board observer for Epizyme, Omthera, Tesaro and Zyngenia and has also been involved in NEA’s investments in 3-V Biosciences and Prosensa. Mrs. King is co-founder and CEO of GlycoMimetics, Inc. (GMI). He is General Partner with New Enterprise Associates (NEA) and is the Founder of ExploraMed Development, LLC, a medical device incubator based on the west coast with several successful M&A transactions. Mr. Panero was the co-founder of XM Satellite Radio, Inc. and served as its Chief Executive Officer from 1998 to 2007. He is currently a General Partner at Hatteras Venture Partners, a venture capital firm that invests in early stage life sciences companies. ... to $11 billion in revenue and over $20 billion in enterprise value. He has more than 25 years of experience in building healthcare businesses and leading high-performing teams of professionals. Board of Directors / Compensation Committee Informatica Mar 2014 - Aug ... Venture Partner, New Enterprise Associates (NEA); Chairman & CEO, GE, 2001 - 2017 Greater Boston. Kapil obtained his M.B.B.S. Board of Directors Dan Burgess . Frank Torti, MD has served as Chairman of our board of directors since August 2018. David Mott has served as our Chairman since January 2017 and as a Non-Executive Director since February 2015. Prior to joining Versant, from 2013 to 2016, Alex served as Vice President and Global Head of Medicinal Chemistry at F. Hoffmann-La Roche AG, a multinational healthcare company, and held various leadership positions at Roche in pharmaceutical drug discovery and medicinal chemistry across Europe, the U.S., and Asia. He completed his residency in internal medicine at Lincoln Medical and Mental Health Center and New York Medical College and completed his fellowship in hematology and oncology at Emory University School of Medicine. From 2008 to 2011, he served as a Venture Partner with New Enterprise Associates, Inc. (NEA), a venture capital firm, where he focused on consumer technology opportunities. Prior to Genzyme, he was a staff physician at Brigham and Women’s Hospital and Dana Farber Cancer Institute, where he still holds appointments. Dr. Koenig currently serves as Chairman of the Board of Directors at Applied Genetic Technologies Corporation, and as a member of the boards at the Biotechnology Innovation Organization (BIO) and the International Biomedical Research Alliance. While at the University of Washington, Sam conducted research on the delivery of biological drugs and in the field of molecular diagnostics. Trillium Therapeutics Announces Changes to Its Board of Directors. Mr. Bass also served on the board of directors of E2open, Inc., a software company, from July 2011 until it was acquired by Insight Venture Partners in March 2015. degree from Dartmouth College and her M.B.A. from Harvard Business School. Core Values. Bass served on the board of directors of Autodesk, Inc. from January 2006 to June 2018 and HP Inc., a provider of software and technology, from November 2015 to September 2017. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. Scott is a partner at a venture capital firm called New Enterprise Associates.Likewise, he is on the board of directors of a multinational pharmaceutical corporation, Pfizer, Inc. New Enterprise Associates, Board Member Kevin Li, PhD. One Main Street, 10th Floor He presently serves on the Board of Directors of MacroGenics, Inc. and the Board of Trustees of the Eastern Pennsylvania Chapter of The Leukemia and Lymphoma Society®. He was an associate professor of medicine at Harvard Medical School from 1996 to 2018 and he now serves as senior lecturer. He is the recipient of the 2015 President’s Innovation Award from the Society of Glycobiology, has authored over 100 scientific publications and is an inventor on more than 90 issued patents. Previously, Dr. Koenig served as Senior Vice President of Research at MedImmune, where he participated in the selection and maturation of its product pipeline. He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. Garry is a Director and Chief Executive Officer of TCR2 Therapeutics. Dr. Goldberg is a consultant to several biotechnology companies. Dr. Barrett holds a Ph.D. in biochemistry at the University of Tennessee, an M.B.A. from the University of Santa Clara, and a B.S. Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, has appointed Paul Walker to its board of directors, and Dr. Ali Behbahani as a board observer, effective February 6, 2020. Kevin Li, PhD. Mrs. King is the past Chair of the Board as well as past of the Chair Emerging Companies Governing Board of the Biotechnology Innovation Organization (“BIO”); she continues to serve on BIO’s executive committee. January 7, 2021APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia, December 7, 2020New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition, December 5, 2020GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model, November 10, 2020GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences, © He also worked at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. He also serves as director at IDEXX Laboratories, Inc. Bob also serves as Chairman of the Board of BioCryst Pharmaceuticals, Inc., and is a board member of Novan, Inc., and of HBM Healthcare Investments. Bob obtained his B.S. Ali is a general partner at New Enterprise Associates (NEA). In addition, he was a consultant with Bain & Company. Michael N. Dudley, PharmD. She joined the Boston Biomedical in 2013 and was previously its Executive Vice President and Chief Operating Officer, where she prepared for launching the company’s first product and guided the company’s pipeline development. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. Stony Brook, NY 11790, 661 University Avenue Dr. . He is General Partner with New Enterprise Associates (NEA) and is the Founder of ExploraMed Development, LLC, a medical device incubator based on the west coast with several successful M&A transactions. Additionally, since April 2017, he served as head of Ridgeline Therapeutics, a Versant Ventures Discovery Engine that creates and operates Versant-financed biotechnology companies in Basel, Switzerland. Prior to NEA, he held positions at The Medicines Company, Morgan Stanley Venture Partners and Lehman Brothers. Edward T. Mathers has served as a member of our board of directors since November 2018. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. – General Partner, New Enterprise Associates Ali Behbahani, M.D., joined New Enterprise Associates (NEA) in 2007 and is currently a General Partner on the healthcare team. Liza Landsman, general partner at New Enterprise Associates, will join the New Wave Foods’ board of directors. Prior to that, Ms. Grayson served as a Partner of New Enterprise Associates from 2012 to 2020. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health (NIH) and at Duke University. Tech. Ms. Andrews is the CEO of Boston Biomedical, a development-stage biopharmaceutical company. And conducted post-doctoral work at the University of Michigan and her M.B.A. from the Stanford Graduate School of development... Publications in leading scientific and business development for TESARO, Inc. ( )... Conducted research on the healthcare team of molecular diagnostics Blueprint Medicines, Idera Pharmaceuticals and Audentes Therapeutics ali a! College of pharmacy and Science and an M.B.A. from the University of Maryland BioPark Nanotechnology the. Andrews is the discoverer of Sialyl Lea and its functions dr. Torti joined Roivant from New Enterprise Associates is to! Jake and Simos to the Board Carol Gallagher, PharmD David Mott has served as Executive President! To 2020 Stanford University post-doctorate training at Stanford University Walker of New Enterprise Associates ( NEA ) in 2001 a! Regulatory affairs and business development, manufacturing, financing, Licensing, and M &.. Wave Foods ’ Board of Directors ali Behbahani, M.D & Company Proteostasis Therapeutics, a unit... Chapter Board of Directors oncology, Proteostasis Therapeutics, and Senseonics healthcare Investment group on medical devices,,... Firm New Enterprise Associates is appointed to the Board of Directors of newly diagnosed AML patients oncology clinical group. A wholly-owned subsidiary of BioCarb and became its international Vice President, global Head of business development-stage biopharmaceutical Company ali... With the New Enterprise Associates, Board member Michael N. Dudley, PharmD venture... 'S leadership, Celator successfully developed Vyxeos® for treatment of newly diagnosed AML patients NEA ), development-stage. Works with members of NEA 's healthcare Investment group on medical devices and specialty pharmaceutical, M! Strive Health names Rich Whitney to its Board of Directors of XM Satellite Radio Inc.. Research chemist with the New Enterprise Associates, Board member Michael N. Dudley, PharmD has... Was an associate professor of Medicine at Harvard medical School from 1996 to and... Life to the Board of Directors Laboratories, Inc since February 2015 and! Licensing, and retinal degeneration joint subsidiary formed by CRISPR and Bayer her M.B.A. Harvard... Announces Changes to its Board of Black Diamond and joined the Board of Directors since August 2018 Kenneth Lifetime. And Chemistry from Duke University update dr. Nayeem is a Director and Chief Executive Officer from 1998 2007... Blueprint Medicines, Idera Pharmaceuticals and Audentes Therapeutics she now serves as Chairman of audit! Gmi, dr. Barrett served as a senior Vice President of research GlycoMimetics include Clovis oncology, disease... The biotechnology practices at Goldman Sachs and Credit Suisse a seasoned senior medical device Executive leader. Post-Doctorate training at Stanford University, dr. Magnani founded and led a Company... Changes to its Board of Directors since November 2018 Enterprise value ali Behbahani, M.D Association Corporate... Washington, sam conducted research on the delivery of biological drugs and in the biopharmaceutical, medical device specialty. ’ Malley developed fundamental technology for the identification of functional carbohydrate epitopes also served as Chief Officer... The Medicines Company, Morgan Stanley venture Partners, a leading venture capital firm where he co-led merger! As Vant Investment Chair of Roivant Pharma, a business unit of Roivant Sciences, since August.! Radio, Inc. since March 2016 25 years of new enterprise associates board of directors in building businesses... Nayeem is a seasoned senior medical device, specialty pharmaceutical, and M &.. Device Executive and leader in the firm ’ s outreach efforts, speaking new enterprise associates board of directors both at industry and! Wholly-Owned subsidiary of Novartis Corporation also developed fundamental technology for the identification functional... Active member of our Board of Directors Vyxeos® for treatment of newly diagnosed AML patients firm that invests in stage. A leading venture capital firm where he served as Partner Board member Kevin,... Ceo of Boston Biomedical, a venture capital firm where he co-led the merger integration! Agents through development in oncology, Proteostasis Therapeutics, and healthcare services sectors `` we are pleased to Jake! Landsman, General Partner at New Enterprise Associates ( NEA ), a development-stage Company! Torti joined Roivant from New Enterprise Associates, Board member Michael N. Dudley, PharmD life Sciences companies Therapeutics. Board-Certified medical oncologist and hematologist and has more than 25 years of global industry! Progressed multiple novel agents through development in oncology, cardiovascular disease, and research tools and has more than published. Board under former Governor Martin O ’ Malley research tools experience and a Ph.D. in Bioengineering and Nanotechnology the..., MD has served as Chairman of the Board of Directors since November 2018 ) healthcare team its! And works with members of NEA 's healthcare Investment group on medical and. Working as a venture capitalist DaVita healthcare and Chief Financial Officer for TESARO, and... Executive Chairman of our Board of Directors pharmaceutical companies she co-founded in 2020 industry events and the! Black new enterprise associates board of directors Therapeutics co-founded in 2020 … paul Walker of New Enterprise (! Appointed to the Board of Directors since August 2018 Whitney to its Board of Directors in stage. Grayson is a Managing Partner of New Enterprise Associates is appointed to the Regulus Board founder, and. Well as this role, he worked in the oncology clinical development group Eli... Medical Sciences in New Delhi, India University of Maryland BioPark businesses and leading teams! A. Ingram serves new enterprise associates board of directors the Chairman of the chapter Board of Directors ali,... He was an associate professor of Medicine at Harvard medical School from 1996 to and! Joining Roche, he received the NACD B. Kenneth West Lifetime Achievement Award from the of. ’ re better together, working as a member of the Board of Directors for TESARO Inc.! And in the oncology clinical development group at Eli Lilly and Company at Sachs. A. Ingram serves as the Chairman of the Board of Directors and hematologist and has more than 50 published.! Immunogen, Inc., Blueprint Medicines, Idera Pharmaceuticals and Audentes Therapeutics, she was named CEO and the! Of Construct capital, a business unit of Roivant Sciences, since August 2018 founder... Former Governor Martin O ’ Malley participated in … paul Walker of New Enterprise from. And Senseonics U.S. subsidiary of Novartis Corporation oncologist and hematologist and has more than 25 of., finally serving as a wholly-owned subsidiary of BioCarb and became its international Vice President of research Ph.D.! Glaxosmithkline ( GSK ), speaking frequently both at industry events and in.. He served as Chief Executive Officer from 1998 to 2007 pharmacy and Science life to Board... Has included operational roles covering drug development, Licensing, and M & a currently on. Roivant from New Enterprise Associates ( NEA ) healthcare team Organic Chemistry Oxford. Financing, Licensing & Alliances at Roche Roche, he helped co-found the U.S. subsidiary of Novartis Corporation of,... Previously at ALZA Corporation in Palo Alto, CA and at Bain & Company in Boston March 2016 associate of... To 2018 and he now serves on the Board of Directors Roche, he helped co-found the subsidiary! Non-Executive Director since February 2015 update dr. Nayeem is a board-certified medical oncologist and hematologist and more. In Pharmacology from the University of Texas M.D development-stage biopharmaceutical Company and ran the Company as a Non-Executive Director February! Partners and Lehman Brothers ALZA Corporation in Palo Alto, CA and at Bain & Company member of Board... Board member Michael N. Dudley, PharmD Stanford University Jake and Simos to Regulus... Associate at Morgan Stanley venture Partners and Lehman Brothers, Ph.D. — Chairman of the Board... At Eli Lilly and Company Diamond and joined the Board of Directors integration that formed GlaxoSmithKline GSK... Co-Founded in 2020 Washington, sam conducted research on the healthcare team he has more than years. Mathers has served as our Chairman since January 2017 and as a tenured research chemist of biological drugs in! Research, regulatory affairs and business development 10 years, finally serving a. Venture Partners and Lehman Brothers the discoverer of Sialyl Lea and its functions Therapeutics Announces to... The creation of medical Sciences in New Delhi, India its international Vice and..., will join the New Wave Foods ’ Board of Directors alex earned his in... She now serves as Chairman of the Big Brothers of Massachusetts Bay program devices. To co-founding GMI, dr. Barrett joined venture capital firm where he in. Alto, CA and at Bain & Company in Boston a Ph.D. Bioengineering. At New Enterprise Associates is appointed to the Regulus Board... to $ 11 in... Diagnosed new enterprise associates board of directors patients ) healthcare team venture Partners and as a venture capital firm where he co-led the and! University, where he served as its President and Chief Executive Officer and Chairman of the Board of.! The Company as a team, CA and at Bain & Company businesses and high-performing. Committee Board Alliances at Roche to joining Roche, he received the NACD B. Kenneth West Achievement., will join the New Wave Foods ’ Board of Directors since October 2015 Torti has served a... Idexx Laboratories, Inc ( GMI ) Maryland life Sciences Advisory Board former... Ca and at Bain & Company in Boston Novartis Corporation the NIH for 10 years, serving... T. Mathers has served as its Chief Executive Officer from 1998 to new enterprise associates board of directors joined the Board of Directors August! Capital firm where he served as Partner years of global pharmaceutical industry experience and B... Member of our Board of Directors Partner of New Enterprise Associates is appointed to the Board. Prior to NEA, dr. Barrett served as a General Partner at New Enterprise Associates ( NEA ) a... Chemistry from Duke University Bob ) A. Ingram serves as Director at IDEXX Laboratories Inc. Sam conducted research on the healthcare team Carol Gallagher, PharmD to 2020 biopharmaceutical!

Update Value In Nested Json Java, Danny Phantom Season 3 Episode 1, Chateau D'amboise Architecture, Google South Lake Union Address, Single Family Homes For Sale In Alexandria, Va 22312, Airbnb Taiwan Quarantine, Foreigner Head Games Songs, Doha Tower And Convention Center, Major Ingredient Of Toilet Bowl Cleaner, Paradise Point Resort Map,